---
title: Development of a Psychosocial Intervention to Reduce Post Traumatic Stress in Young Adult Survivors of Cancer
nct_id: NCT07160933
overall_status: NOT_YET_RECRUITING
phase: NA
sponsor: Zeba Ahmad, Ph.D.
study_type: INTERVENTIONAL
primary_condition: Post-traumatic Stress Symptoms
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07160933.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07160933"
ct_last_update_post_date: 2026-03-31
last_seen_at: "2026-05-12T06:42:19.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Development of a Psychosocial Intervention to Reduce Post Traumatic Stress in Young Adult Survivors of Cancer

**Official Title:** Adaptation and Refinement of a Psychosocial Intervention to Reduce Post-Traumatic Stress in Young Adult Survivors of Cancer

**NCT ID:** [NCT07160933](https://clinicaltrials.gov/study/NCT07160933)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 80
- **Lead Sponsor:** Zeba Ahmad, Ph.D.
- **Collaborators:** American Cancer Society, Inc.
- **Conditions:** Post-traumatic Stress Symptoms
- **Start Date:** 2026-04-15
- **Completion Date:** 2030-06-30
- **CT.gov Last Update:** 2026-03-31

## Brief Summary

The goal of this study is to develop a virtual group intervention to address post-traumatic stress related to cancer in young adult cancer survivors (YACs, aged 18-39). The study team will do this by integrating evidence-guided treatments and expert clinician feedback (N=10) on the content, delivery, and structure of the intervention. Next, the study team will refine this intervention through a pilot trial with a group of YACs (N=80).

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 39 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria: To be eligible for this study, participants will be:

* Currently aged between 18 - 39;
* Currently receiving or having completed treatment for cancer at the Mass General Cancer Institute within the past 5 years;
* Reporting a score denoting at least mild symptoms of PTSD on the Post-traumatic Stress Checklist 5 (PCL-5);
* English-speaking;
* Have access to a device with audio/video capabilities to complete virtual intervention sessions.

Exclusion Criteria:

* Unable to provide verbal consent
* Reporting active symptoms of psychosis that preclude safe participation.
```

## Arms

- **Psychosocial Intervention for Cancer-Related Post-Traumatic Stress in Young Adults** (EXPERIMENTAL) — The study team aims to evaluate the feasibility and acceptability of the adapted psychosocial intervention through a pilot trial with a group of 80 YACs, followed by mixed-methods data analysis of feasibility and acceptability outcomes.

## Interventions

- **Psychosocial Intervention for Cancer-Related Post-Traumatic Stress in Young Adults** (BEHAVIORAL) — A new group-based virtual intervention to address post-traumatic stress related to cancer in YACs, integrating evidence-guided treatments from Cognitive Processing Therapy and Mind-Body Resiliency interventions.

## Primary Outcomes

- **Intervention Feasibility: Percent of Identified Prospective Participants Who Enroll** _(time frame: Post-treatment completion (enrollment to treatment completion is approximately 3 months))_ — Percent of eligible participants who were offered participation and who enroll in the study by completing consent and baseline assessment.
- **Intervention Feasibility: Proportion of Participants Completing the Program** _(time frame: Post-treatment completion (enrollment to treatment completion is approximately 3 months))_ — Percent of enrolled participants who complete the program, defined as completing 6 out of 8 sessions.
- **Intervention Acceptability** _(time frame: Post-treatment completion (enrollment to treatment completion is approximately 3 months))_ — Acceptability will be assessed by the Client Satisfaction Questionnaire (CSQ-8). The intervention study will be considered acceptable if ≥80% of participants rate it as acceptable (defined as a CSQ-8 score ≥20).

## Locations (1)

- Mass General Cancer Center, Boston, Massachusetts, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.mass general cancer center|boston|massachusetts|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07160933.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07160933*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*